Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025

Stock Track

2024-12-10

BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.

Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:

The Chinese government's supportive policy on innovative drugs and pricing
An expected improvement in biotech funding environment

According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/1183254431"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1183254431\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/1183254431?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-10 22:34","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1183254431","market":"us","top_or_hot":-1,"title":"Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025","media":"Stock Track","content":"<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.</p>\n\n<p>Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:</p>\n\n<ul>\n<li>The Chinese government's supportive policy on innovative drugs and pricing</li>\n<li>An expected improvement in biotech funding environment</li>\n</ul>\n\n<p>According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | BeiGene Stock Plummets 5.83% on Tuesday, Recovery Expected in 2025\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2024-12-10 22:34</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.</p>\n\n<p>Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:</p>\n\n<ul>\n<li>The Chinese government's supportive policy on innovative drugs and pricing</li>\n<li>An expected improvement in biotech funding environment</li>\n</ul>\n\n<p>According to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"","article_id":"1183254431","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1183254431","pubTimestamp":1733841298,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"BeiGene, a Chinese biopharmaceutical company, saw its stock  plummet by 5.83% on Tuesday during the intraday trading session.Despite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:. The Chinese government's supportive policy on innovative drugs and pricing. According to Cyrus Ng, an analyst at Deuts","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"股票赛道百济神州股价周二暴跌5.83%预计2025年复苏","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BGNE":1},"content_text":"BeiGene, a Chinese biopharmaceutical company, saw its stock (BGNE) plummet by 5.83% on Tuesday during the intraday trading session.\nDespite the plunge, analysts at Deutsche Bank believe that the recovery momentum seen in China's healthcare companies, including BeiGene, since mid-August is expected to continue in 2025. This recovery is anticipated to be driven by the following factors:\n\nThe Chinese government's supportive policy on innovative drugs and pricing\nAn expected improvement in biotech funding environment\n\nAccording to Cyrus Ng, an analyst at Deutsche Bank, China's healthcare stocks have lagged behind the Hang Seng Index in 2024 amid geopolitical tensions and a difficult biotech funding environment. However, with improved sentiment and the government's supportive measures, China's biotech funding is expected to start recovering gradually in 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}